Form 4: Dyne Therapeutics Director Jason Rhodes Disposes of Shares Under 10b5-1 Trading Plans

Director Jason Rhodes reports the sale of Dyne Therapeutics (DYN) common stock through multiple transactions executed under pre-arranged Rule 10b5-1 trading plans.

Summary

• Jason Rhodes, a director of Dyne Therapeutics, reported the sale of common stock over three days from February 26 to February 28, 2024.
• The sales were executed under Rule 10b5-1 trading plans adopted on January 10, 2024, by Atlas Venture Fund XI, L.P., Atlas Venture Opportunity Fund I, L.P., and Atlas Venture Opportunity Fund II, L.P.
• The transactions involved multiple sales at weighted average prices ranging from $22.83 to $25.255 per share.
• The shares are indirectly held through various Atlas Venture funds, with Rhodes disclaiming beneficial ownership except to the extent of his pecuniary interest.
• The total number of shares sold directly by Rhodes was 973,172.
• Following these transactions, the number of shares indirectly held by Atlas Venture Fund XI, L.P. is 5,698,091.
• Following these transactions, the number of shares indirectly held by Atlas Venture Opportunity Fund I, L.P. is 1,488,126.
• Following these transactions, the number of shares indirectly held by Atlas Venture Opportunity Fund II, L.P. is 864,487.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned and do not necessarily indicate a negative outlook on the company. However, large insider sales can sometimes create uncertainty.

Negatives

• The director's sale of shares, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• Continued sales by insiders could create downward pressure on the stock price.
• The market may react negatively to the ongoing disposal of shares by a director, even if planned.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. However, the market often scrutinizes these transactions for potential signals about the company's future prospects.

Comparison to Industry Standards

• It is common for directors and officers of publicly traded companies, especially in the biotech industry, to utilize 10b5-1 trading plans to diversify their holdings or manage personal finances.
• Comparable companies such as Sarepta Therapeutics or BioMarin Pharmaceutical also see insider transactions, often under similar pre-arranged plans.
• The scale of these transactions is typical for venture-backed companies where early investors and directors hold significant equity positions.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price in the short term.
• Employees may be concerned about the reasons behind the sales, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates